Drugs@FDA: FDA Approved Drug Products

Home | Previous Page

Abbreviated New Drug Application (ANDA): 206936
Company: MYLAN PHARMS INC
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
GLATIRAMER ACETATE GLATIRAMER ACETATE 40MG/ML INJECTABLE;SUBCUTANEOUS Prescription AP No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
10/03/2017 ORIG-1 Approval STANDARD Letter (PDF)

Label is not available on this site.

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206936Orig1s000ltr.pdf

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS; 40MG/ML
TE Code = AP

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
COPAXONE GLATIRAMER ACETATE 40MG/ML INJECTABLE;SUBCUTANEOUS Prescription Yes AP 020622 TEVA PHARMS USA
GLATIRAMER ACETATE GLATIRAMER ACETATE 40MG/ML INJECTABLE;SUBCUTANEOUS Prescription No AP 206936 MYLAN PHARMS INC
GLATOPA GLATIRAMER ACETATE 40MG/ML INJECTABLE;SUBCUTANEOUS Prescription No AP 206921 SANDOZ INC

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English